1. FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials. (15th June 2017) Authors: Mease, PJ; Marzo-Ortega, H; Poder, A; Bosch, F Van den; Wollenhaupt, J; Lespessailles, E; McIlraith, M; Teng, L; Hall, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗